Siltuximab: First Global Approval

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

(2014) J. San-Miguel et al.   BLOOD

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

(2013) Peter M. Voorhees et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease

(2013) R. Kurzrock et al.   CLINICAL CANCER RESEARCH

Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

(2011) Sally A. Hunsucker et al.   BRITISH JOURNAL OF HAEMATOLOGY

Abstract 5331: Interleukin-6 as a therapeutic target in advanced ovarian cancer

(2011) Jermaine Coward et al.   CANCER RESEARCH

Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics

(2011) H. E. El-Osta et al.   ONCOLOGIST

The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study

(2011) Jayaprakash Karkera et al.   PROSTATE

Pharmacokinetic and Pharmacodynamic Modeling of an Anti-Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma

(2010) T. Puchalski et al.   CLINICAL CANCER RESEARCH

Effects of Siltuximab on the IL-6-Induced Signaling Pathway in Ovarian Cancer

(2010) Y. Guo et al.   CLINICAL CANCER RESEARCH

Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death

(2009) Peter M. Voorhees et al.   BRITISH JOURNAL OF HAEMATOLOGY